FHIweekly 9/22/22: FDA and stem cells + Diagnoses and treatments need to be transparent

September 22, 2022 | Volume XIII | Issue 38

Shame not on us: Diagnoses and treatments need to be transparent

Susan Salenger writes in a KevinMD blog post:

In Australia recently, a woman successfully sued a hospital for $2.4 million for a series of misdiagnoses that left her quadriplegic. A London woman was recently misdiagnosed four times before doctors discovered she had cervical cancer.

A Canadian woman recently filed a $3.5 million lawsuit claiming she was misdiagnosed and ignored when relaying her symptoms to doctors; she could have died. A 26-year-old woman nearly died after a misdiagnosis of her neurological condition, Guillain-Barré syndrome.

What does shame have to do with this?

Many women blame themselves for becoming ill and feel ashamed about their symptoms, which I discovered in my latest book research. Many report an accurate diagnosis helps relieve some of that shame.

FDA and Stem Cells: Update

Florida Healthcare Law Firm

There was a big update in the stem cell industry recently as a California judge issued a favorable order on behalf of a California based stem cell treatment provider. California Stem Cell Treatment Center, Inc., is a California based medical company offering SVF surgical procedures and MSC surgical procedures. A few years ago, the Food and Drug Administration (FDA) sought an injunction against the Company to prevent them from performing these procedures because the FDA claimed that the procedures included the adulteration of drugs which were then re-injected into the patient and thus were classified as “drugs” and therefore under the FDA purview. The Company argued, however, that the SVF procedure and MSC procedure are not “drugs” as defined by the FDA and there that the procedures don’t fall under the FDA’s definition/prohibition regarding adulteration and misbranding of products. The Court allowed the trial to move forward, and the Company provided support of their position which ultimately was successful.

Learn More

Preventive Services Task Force releases new advice on mental health

Frank Diamond reports for Fierce Healthcare:

The battle for better mental health care might have gotten a big boost as the U.S. Preventive Services Task Force (USPSTF) issued drafts of two separate but related recommendations: one on depression and suicide, and one on anxiety.

Though depression has been on the task force’s radar since 2009, this is the first time the panel has made a recommendation about screening for anxiety.

Mortality rates from prostate cancer is higher in western US states, like Colorado

Where you live may have a great impact on your chances of dying of cancer. According to the American Cancer Society's chief scientific officer, states in the western United States have the highest mortality rate among non-Hispanic white males in the country when it comes to prostate cancer.

Watch the video HERE.

Inside

FloridaHealthIndustry.com

Publisher of Week in Review, Specialty Focus, FHIweekly & Game Changers